Vancouver, British Columbia--(Newsfile Corp. - November 28, 2024) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") announces that in connection with the ongoing Canada Post labour strike, the notice of meeting, management information circular, and form of proxy (the "Meeting Materials") for the upcoming annual general and special meeting (the "Meeting") of holders (the "Shareholders") of Common shares ("Common Shares") of the Company, can be accessed under Kovo's SEDAR+ profile on www.sedarplus.ca and through Kovo's website at www.kovo.co/agm.
Registered Shareholders
The Company is encouraging Registered Shareholders to access the Meeting Materials electronically and vote their Common Shares online. Registered Shareholders can request copies of the Meeting Materials delivered via email by contacting Computershare Trust Company of Canada ("Computershare"), Kovo's registrar and transfer agent, at 1-800-564-6253 (Toll-Free North America) or 1-514-982-7555 (Toll-Free International).
Beneficial Shareholders
Beneficial Shareholders should contact their broker/intermediary to obtain a copy of their voting instruction form or other proxy-related materials if not already provided.
Proxies and Questions
In all cases, Shareholders' votes must be received not later than 10:00 a.m. (MST) on December 12, 2024 or not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time for the holding of the Meeting or any adjournment thereof.
Shareholders with questions on voting may contact Computershare at 1-800-564-6253 (Toll-Free North America) or 1-514-982-7555 (Toll-Free International), or the Company at This email address is being protected from spambots. You need JavaScript enabled to view it..
About Kovo+ Holdings Inc.
Kovo+ is a versatile technology company leading the charge in AI initiatives to drive impact and innovation across diverse industries. Kovo+ remains committed to its core business-model of strategic growth opportunities within mid-market Medical Billing firms, where exploitive business optimization synergies exist. Moving forward, Kovo+ will integrate accretive broader healthcare sector additions to its portfolio and opportunities beyond in multiple new markets. Dedicated to revolutionizing business processes optimization through technological advancements and evolving AI applied methods, Kovo+ embodies a commitment to ensured and enduring profitability. To learn more about Kovo+ and to keep up to date on Kovo+ news, visit www.kovoplus.co.
Contact Information
For further information, please contact:
Peter Bak
Board Chair
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-866-558-6777
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.
| Last Trade: | C$0.06 |
| Daily Volume: | 0 |
| Market Cap: | C$7.990M |
December 12, 2024 December 11, 2024 October 11, 2024 September 30, 2024 September 11, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
